First-level Neurocognitive Screening Tests and Their Application

Finding an effective therapy able to slow Neurocognitive Disorder’s (NCD) progression represents an ambitious purpose of biomedical research. In June 2021, the Food and Drug Administration approved Aducanumab for the treatment of Alzheimer’s disease – the most common cause of dementia worldwide [1]. This drug is a monoclonal antibody that would be cause amyloid-β plaques reduction in the brain [2]. Whether its effectiveness will be confirmed or not, the fact remains that the patients that will benefit the most from any treatment are the ones suffering from mild NCD. Mild NCD is a clinically insidious and difficult-to-diagnose disorder, and consequently, the development and the spread of screening methods are necessary to early intercept these subjects.